The present findings documented that patients with OSA show cerebral glucose consumption dysregulation, CSF AD biomarker alterations (both p-tau proteins and Aβ42) and cognitive impairment, thus highlighting the importance of increasing OSA screening and diagnosis in the middle-aged adult and elderly population, since CPAP treatment may improve cognitive performance and possibly restore brain functioning. The gene discussed is MAPT; the disease is Alzheimer disease.